Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005;9(6):R596-600.
doi: 10.1186/cc3808. Epub 2005 Sep 19.

Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis

Affiliations
Clinical Trial

Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis

Jordan Kountchev et al. Crit Care. 2005.

Abstract

Introduction: In acute disseminated intravascular coagulation, the effect of antithrombin (AT) administration on elevated levels of D-dimer is not well established. In the present study, we report on changes in circulating levels of D-dimer in response to administration of AT in a series of patients with acquired AT deficiency due to severe sepsis.

Methods: Eight consecutive critically ill medical patients presenting with acute disseminated intravascular coagulation associated with severe sepsis/septic shock received a single bolus infusion of AT over 30 minutes, aiming to achieve physiological AT levels. Haemostatic parameters including D-dimer were assessed prior to, 6 and 24 h after AT administration. An average of 42 +/- 9 U/kg body weight was infused.

Results: Following AT substitution, elevated levels of D-dimer fell whereas AT levels rose.

Conclusion: These observations support the notion that AT can favourably affect fibrin degradation accompanying disseminated intravascular coagulation of severe sepsis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of antithrombin (AT) substitution on D-dimer levels (results are given as mean ± SEM, n = 6; patients receiving low-dose unfractioned heparin not included; *p < 0.05).
Figure 2
Figure 2
Effect of antithrombin (AT) on D-dimer levels in individual patients. D-dimer levels were assessed 4 to 6 h prior to, and 6 and 24 h after AT administration. Patients 7 and 8 were concomitantly receiving low-dose unfractioned heparin for continuous renal replacement therapy.

Comment in

Similar articles

Cited by

References

    1. Okabayashi K, Wada H, Ohta S, Shiku H, Nobori T, Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004;76:225–229. doi: 10.1002/ajh.20089. - DOI - PubMed
    1. de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. Current drug treatment strategies for disseminated intravascular coagulation. Drugs. 1998;55:767–777. - PubMed
    1. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663–672. doi: 10.1007/s001340050642. - DOI - PubMed
    1. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc. 2001;286:1869–1878. doi: 10.1001/jama.286.15.1869. - DOI - PubMed
    1. DePalo V, Kessler C, Opal SM. Success or failure in phase III sepsis trials: Comparisons between drotrecogin alpha (activated) and antithrombin III clinical trials. Adv Sepsis. 2001;1:114–124.

Publication types